The UK Gill Heart & Vascular Institute provides the region’s only expertise in the management of pulmonary hypertension. Many of our patients are referred from other area hospitals for treatment.

Our program includes an expert team of cardiologists, pulmonologists and nurse practitioners who work together to help patients who have the condition across all five groups delineated by the World Health Organization:

• Pulmonary arterial hypertension (PAH).
• PH secondary to disease of the left side of the heart.
• PH due to chronic lung disease and resultant low oxygen levels.
• Chronic thromboembolic pulmonary hypertension (CTEPH).
• PH due to other miscellaneous causes.

Through collaboration with other units across Gill, our multidisciplinary team utilizes heart catheterization, echocardiogram and lung functioning tests to efficiently and accurately obtain a diagnosis. The most common course of treatment is medication therapy; however, for those who do not respond sufficiently to treatment, our program is able to facilitate transition to the UK Transplant Center to identify good candidates for lung or lung/heart transplantation.

Our team remains at the forefront of medical therapy by participating in a range of clinical trials. This ensures that we are able to provide the most advanced medical care to our sickest patients.

Learn more about our Pulmonary Hypertension ProgramSee more stories from 2018 State of the Heart